Bluelinx Holdings Inc. – Consensus Indicates Potential 55.0% Upside

DirectorsTalk Interviews

Bluelinx Holdings Inc. with ticker code (BXC) now have 5 analysts covering the stock. The analyst consensus points to a rating of ‘Buy’. The range between the high target price and low target price is between 127 and 100 calculating the average target price we see 108.4. Now with the previous closing price of 69.92 this is indicating there is a potential upside of 55.0%. The day 50 moving average is 74.52 and the 200 moving average now moves to 77.96. The market capitalisation for the company is $660m. Company Website: https://www.bluelinxco.com

The potential market cap would be $1,024m based on the market concensus.

BlueLinx Holdings Inc., together with its subsidiaries, distributes residential and commercial building products in the United States. The company distributes specialty products comprising engineered wood, industrial products, cedar, moulding, siding, metal, and insulation products; and structural products include lumber, plywood, oriented strand boards, rebars and remesh, spruce, and other wood products primarily that are used for structural support in construction projects. It also provides various value-added services and solutions to customers and suppliers. The company serves dealers, specialty distributors, national home centers, and manufactured housing customers through a network of distribution centers. BlueLinx Holdings Inc. was incorporated in 2004 and is headquartered in Marietta, Georgia.

Share on:

Latest Company News

Genflow Biosciences reports early findings from SIRT6 gene therapy study

Genflow Biosciences reports early findings from its SIRT6 gene therapy study in older dogs, with further monitoring planned over...

Ilika CEO to discuss battery gigafactory development at Barcelona industry forum

Ilika CEO Graeme Purdy is set to speak at the December 2026 Barcelona battery gigafactory forum, bringing the company's...

Investors demand clear returns as AI spending comes under scrutiny

Investors are demanding clearer returns from AI spending as technology shares face pressure, with corporate earnings, data centre investment...

Novo Nordisk deal puts focus on next generation of oral GLP-1 treatments

Novo Nordisk secures rights to Hengrui's investigational HRS-1596 in a potential $2.6bn deal, targeting the development of once-weekly oral...

itim Group targets retail AI market with new platform launch

ITIM Group is targeting the retail AI market with itimAIQ, a new platform designed to automate operations, improve efficiency...

Drax sets date for 2026 Capital Markets Day and trading update

Drax Group will host its Capital Markets Day on 23 November 2026, providing investors and analysts with a management...

    Search